Product Description: Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
Applications: Neuroscience-Neuromodulation
Formula: C25H27N3O2S
References: [1]Ishima T, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25(4):505-11./[2]Yoshimi N, et al. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25(3):356-64.
CAS Number: 913611-97-9
Molecular Weight: 433.57
Compound Purity: 99.85
Research Area: Neurological Disease
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 80°C)
Target: 5-HT Receptor;Adrenergic Receptor;Dopamine Receptor
Deutsch
English
